Allena Pharmaceuticals, Inc. (ALNA): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALNA Stock Price Chart Interactive Chart >
ALNA Price/Volume Stats
|Current price||$0.21||52-week high||$1.45|
|Prev. close||$0.19||52-week low||$0.07|
|Day high||$0.33||Avg. volume||13,369,978|
|50-day MA||$0.14||Dividend yield||N/A|
|200-day MA||$0.48||Market Cap||22.84M|
Allena Pharmaceuticals, Inc. (ALNA) Company Bio
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company’s lead product candidate includes ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It is also involved in developing ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is based in Newton, Massachusetts.
Most Popular Stories View All
ALNA Latest News Stream
|Loading, please wait...|
ALNA Latest Social Stream
View Full ALNA Social Stream
Latest ALNA News From Around the Web
Below are the latest news stories about Allena Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALNA as an investment opportunity.
No summary available.
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Allena Pharmaceuticals (ALNA – Research Report) and Unity Biotechnology (UBX – Research Report) with bullish sentiments. Allena Pharmaceuticals (ALNA) Wedbush analyst Liana Moussatos reiterated a Buy rating on Allena Pharmaceuticals today and set a price target of $4.00. The company's shares closed last Tuesday at $0.58. According to TipRanks.
B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Allena Pharmaceuticals (ALNA – Research Report) today and set a price target of $4.00. The company's shares closed last Wednesday at $0.51. According to TipRanks.com, Mamtani is a 1-star analyst with an average return of -0.2% and a 36.6% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Spectrum Pharmaceuticals. Allena Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $6.33, which is a 1052.2% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $11.
Analysts Offer Insights on Healthcare Companies: Oncternal Therapeutics (ONCT), Allena Pharmaceuticals (ALNA) and Gritstone Oncology (GRTS)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oncternal Therapeutics (ONCT – Research Report), Allena Pharmaceuticals (ALNA – Research Report) and Gritstone Oncology (GRTS – Research Report) with bullish sentiments. Oncternal Therapeutics (ONCT) H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oncternal Therapeutics today and set a price target of $9.00. The company's shares closed last Tuesday at $2.34. According to TipRanks.
ALLN-346, an orally administered enzyme in development for the treatment of hyperuricemia and gout, demonstrates a statistically significant reduction in serum uric acid and a well-tolerated safety profile in first cohort of patients with hyperuricemia and chronic kidney disease in the Phase 2a Study 201 Allena to host webinar to discuss the initial Study 201 data with Key Opinion Leaders Robert Terkeltaub, M.D. and David S. Goldfarb, M.D. today at 8:00 am ET; log-in information belowALLN-346 Ph
ALNA Price Returns